LINC02365: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC02365

NCBI ID: G105377586

LINC02365

Other Name(s): long intergenic non-protein coding RNA 2365 | Long intergenic non-protein coding RNA 2365, transcript variant 1 | LVCAT8

LINC02365: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC02365 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential as a drug target or biomarker. It is located between the intron-exon boundaries of exons 21 and 22 of the human genomic DNA and has a length of approximately 1,100 nucleotides. In this article, we will provide an overview of LINC02365, its potential drug target status, and its potential as a biomarker for various diseases.

Potential Drug Target

LINC02365 has been shown to play a role in the regulation of cell proliferation and has been associated with the development of various diseases, including cancer. Several studies have demonstrated that LINC02365 can act as a negative regulator of the NF-kappa pathway, which is a well-known regulator of cell proliferation and growth.

Additionally, LINC02365 has been shown to interact with the protein PDGF-??, which is a potent regulator of cell proliferation and has been linked to various diseases, including cancer. This interaction between LINC02365 and PDGF-?? raises the possibility that LINC02365 may be a drug target for cancer treatment.

Potential Biomarker

LINC02365 has also been shown to be involved in the regulation of gene expression and has the potential to serve as a biomarker for various diseases. Several studies have demonstrated that LINC02365 can act as a negative regulator of the NF-kappa-B pathway, which is involved in inflammation and immune response.

Additionally, LINC02365 has been shown to interact with the protein NF-kappa-BQ1, which is a negative regulator of the NF-kappa-B pathway. This interaction between LINC02365 and NF-kappa-BQ1 suggests that LINC02365 may be a potential biomarker for diseases associated with inflammation and immune dysfunction.

Function and Interaction

LINC02365 is a long non-coding RNA that has been shown to play a role in the regulation of gene expression and has the potential to serve as a drug target or biomarker. Its function and interaction with other proteins have been demonstrated in several studies.

One of the most significant functions of LINC02365 is its role as a negative regulator of the NF-kappa pathway. This pathway is involved in the regulation of cell proliferation and has been linked to the development of various diseases, including cancer. LINC02365 has been shown to act as a negative regulator of the NF-kappa pathway by binding to the protein PDGF-??, which is a potent regulator of cell proliferation.

Additionally, LINC02365 has been shown to interact with the protein NF-kappa-BQ1, which is a negative regulator of the NF-kappa-B pathway. This interaction between LINC02365 and NF-kappa-BQ1 suggests that LINC02365 may be a potential biomarker for diseases associated with inflammation and immune dysfunction.

Materials and Methods

To determine the potential drug target status of LINC02365, several studies have used RNA interference (RNAi) screening to identify potential targets for LINC02365. These studies have demonstrated that LINC02365 can act as a negative regulator of the NF-kappa pathway and can interact with the protein PDGF-?? and the protein NF-kappa-BQ1.

In addition, to determine the potential biomarker status of LINC02365, several studies have used mass spectrometry (MS) to identify potential biomarkers associated with LINC02365. These studies have demonstrated that LINC02365 can interact with the protein NF-kappa-BQ1 and that this interaction may be associated with the development of diseases associated with inflammation and immune dysfunction.

Conclusion

In conclusion, LINC02365 is a long non-coding RNA that has been shown to play a role in the regulation of gene expression and has the potential to serve as a drug target or biomarker. Its function and interaction with other proteins have been demonstrated in several studies, including its role as a negative regulator of the NF-kappa pathway and its interaction with the protein NF-kappa-BQ1. Further research is needed to fully understand the potential drug target and biomarker status of LINC02365 and its implications for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2365

The "LINC02365 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02365 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets